rs8099917 — IFNL3

IFNL3 Upstream — The Second Signal in Hepatitis C Immunity

Eight kilobases upstream of the interferon lambda-3 gene (IFNL3, formerly IL28B) on chromosome 19q13.13 sits a T/G polymorphism that has shaped how hepatitis C is treated across the world. The rs8099917 variant lies in the intergenic region between IFNL2 and IFNL3 and, like its more famous neighbour rs12979860, tags the same underlying interferon lambda locus haplotype¹¹ interferon lambda locus haplotype
a cluster of variants in the IFNL2/3/4 region that collectively control innate antiviral immunity at hepatic and mucosal surfaces.

rs8099917 was actually the primary GWAS signal reported by Suppiah et al. in 2009²² Suppiah et al. in 2009 — the study that first identified the IL28B region as the most powerful host genetic predictor of hepatitis C treatment response. In that landmark Australian study, the G allele was associated with an OR of 1.98 for sustained virologic response (SVR) failure. The rs12979860 variant only emerged as the more commonly cited marker after subsequent studies found it slightly more predictive in European populations, but for Asian patients rs8099917 has consistently proven to be the more informative marker.

The Mechanism

rs8099917 sits in an intergenic regulatory region and does not directly alter any protein sequence. Its effect is mediated through linkage disequilibrium³³ linkage disequilibrium
non-random co-inheritance with nearby functional variants across the IFNL3/4 locus, most importantly with the ss469415590 (rs368234815) frameshift that determines whether a functional IFNL4 protein is produced, and with regulatory elements controlling IFNL3 (IFN-λ3) transcription. The G allele at rs8099917 tags the haplotype associated with active IFNL4 production and altered IFNL3 expression — a state that paradoxically impairs viral clearance by inducing ER stress in hepatocytes and pre-activating interferon-stimulated genes⁴⁴ ER stress in hepatocytes and pre-activating interferon-stimulated genes
chronic ISG pre-activation desensitises hepatocytes to exogenous interferon treatment, reducing responsiveness to both endogenous and therapeutic interferon.

The correlation between rs8099917 and rs12979860 varies substantially by ancestry — r²=0.43–0.65 depending on the population studied. This partial independence is clinically meaningful: among Japanese patients, rs8099917 captures predictive signal that rs12979860 misses, because the two markers tag partially different portions of the underlying functional haplotype structure.

The Evidence

The Suppiah et al. 2009 GWAS⁵⁵ Suppiah et al. 2009 GWAS in 293 Australian patients (validated in 555 additional individuals) reported rs8099917 as the primary discovery signal for SVR to peginterferon/ribavirin, with combined OR 1.98 (95% CI 1.57–2.52, p=9.25×10⁻⁹). Simultaneously, Tanaka et al.⁶⁶ Tanaka et al. identified rs8099917 among the strongest predictors of treatment response in Japanese HCV genotype 1 patients, with SVR rates declining sharply from TT to TG to GG carriers.

A meta-analysis of 36 studies comprising 10,912 patients⁷⁷ meta-analysis of 36 studies comprising 10,912 patients quantified the TT genotype effect: in HCV genotype 1/4 patients receiving peginterferon/ribavirin, TT carriers achieved higher SVR versus non-TT with OR 2.54 (95% CI 2.11–3.07) in Caucasians and OR 5.21 (95% CI 3.69–7.36) in Asians — the stronger Asian effect reflecting the higher G allele heterozygosity in that population, where most unfavourable patients carry a single G allele rather than two.

For spontaneous clearance, a Japanese cross-sectional study⁸⁸ Japanese cross-sectional study found TT genotype was independently associated with spontaneous HCV elimination with an adjusted OR of 9.39 in multivariate analysis including sex and age. A separate meta-analysis of spontaneous clearance studies⁹⁹ meta-analysis of spontaneous clearance studies confirmed the association and specifically noted that in East Asian populations, rs8099917 appeared to be a stronger predictor than rs12979860.

With modern direct-acting antivirals (DAAs), the rs8099917 genotype retains some clinical relevance. Like its partner rs12979860, the G allele predicts slower early viral decay kinetics even with sofosbuvir-based therapy, and GG homozygotes may benefit less from abbreviated 8-week treatment protocols. However, overall SVR rates with modern pangenotypic DAA regimens exceed 95% regardless of IFNL3 genotype when standard 12-week durations are used.

Practical Actions

Carriers of one or two G alleles who have hepatitis C or are at risk should share their genotype with their hepatologist when planning treatment. For interferon-era therapy, the genotype was highly determinative; for modern DAA therapy, it primarily affects whether abbreviated treatment courses are appropriate rather than whether cure is achievable.

The variant's relevance extends to treatment monitoring: the G allele predicts slower early viral decay kinetics, meaning earlier time points (week 4 viral load) carry more prognostic weight for G-allele carriers on DAA therapy.

Interactions

rs8099917 is in partial linkage disequilibrium with rs12979860¹⁰¹⁰ rs12979860
the more commonly cited IL28B locus marker; r²=0.43–0.65 depending on population — partial independence means both SNPs provide additional information, and with rs368234815¹¹¹¹ rs368234815
the ss469415590 frameshift that creates or destroys functional IFNL4 protein — the true causal variant that both rs8099917 and rs12979860 tag. Clinical HCV pharmacogenomics panels frequently report both rs8099917 and rs12979860 together because neither alone is sufficient across all ancestries — the combination provides near-complete haplotype information.